Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review
Authors:
- Kathryn M. CurtisKCKathryn M. Curtis
- Summer L. MartinsSMSummer L. Martins
- Herbert B. PetersonHPHerbert B. Peterson
- 1 February 2006
- journal article
- review article
- Published by Elsevier in Contraception
- Vol. 73 (2) , 166-178
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Oral Contraceptives and the Risk of Venous ThrombosisNew England Journal of Medicine, 2001
- Post-marketing surveillance of Norplant® contraceptive implants: II. Non-reproductive healthContraception, 2001
- Oral Contraception and Factor V Leiden Mutation in Relation to Localization of Deep Vein ThrombosisThrombosis Research, 1998
- Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptivesContraception, 1998
- Geographic Distribution of the 20210 G to A Prothrombin VariantThrombosis and Haemostasis, 1998
- Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening1997
- World distribution of factor V LeidenThe Lancet, 1995
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994
- Prevalence of antithrombin deficiency in the healthy populationBritish Journal of Haematology, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993